Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial

This phase I trial tests the safety, side effects, and best dose of FH-FOLR1 ST chimeric antigen receptor (CAR) T cells and how well they work in treating patients with osteosarcoma that recurred or spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has not responded to previous treatment (refractory) or has come back after a period of improvement (recurrent)/is growing, spreading, or getting worse (progressive). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in th

Trial Details

NCT ID

NCT07227571

Phase

PHASE1

Sponsor

Fred Hutchinson Cancer Center

Status

RECRUITING

Cancer Type

Osteosarcoma Sarcoma

Interventions

FH FOLR1 ST CAR T-cells
Leukapheresis
Fludarabine
Cyclophosphamide
Echocardiography Test
Multigated Acquisition Scan

Locations (sample)

Seattle, Washington, United States|47.60621,-122.33207

Key Eligibility Criteria

Age 1-75 years at the time of enrollment
Tissue confirmation of osteosarcoma diagnosis
Must have received an anthracycline-based regimen or been deemed ineligible to receive this therapy
Must have at least one of the following in the 6 months prior to trial consent:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →